TrialCancer medicine2026

A Randomized Trial of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or FOLFIRI/Cetuximab in Chinese Patients With BRAF

Wang Xicheng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.